Phase IIb dose-finding study to evaluate the safety and efficacy of Bavisant in the treatment of excessive daytime comnolence (EDS) in patients with Parkinson's disease (PD). CASPAR study
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: BENEVOLENTAI BIO
- Phase: II
- Execution start: 30/10/2018
- End of execution: 30/03/2020
- PI: ADOLFO MINGUEZ CASTELLANOS